Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.59 |
| ▸ | PLK3 | Q9H4B4 | 12/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3736969 | 0.91 | PLK1 (0.60) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL3741864 | 0.91 | PLK1 (0.60) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL3742954 | 0.90 | PLK1 (0.73) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL3742613 | 0.89 | PLK1 (0.55) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL3739918 | 0.89 | PLK1 (0.55) | PLK1PLK3CDK2IKBKE | |
| SCHEMBL3740923 | 0.88 | PLK1 (0.58) | PLK1PLK3CDK2IKBKECYP2C9 | |
| SCHEMBL3737290 | 0.88 | PLK1 (0.74) | PLK1PLK3CYP2C9CYP3A4 | |
| SCHEMBL3737966 | 0.88 | PLK1 (0.74) | PLK1PLK3CYP2C9CYP3A4 | |
| SCHEMBL3741480 | 0.88 | PLK1 (0.74) | PLK1PLK3CYP2C9CYP3A4 | |
| SCHEMBL3739945 | 0.88 | PLK1 (0.65) | PLK1PLK3CDK2IKBKECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273890-B2 | Thiophene-imidazopyridines | 4SC AG (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2009003911-A1 | THIOPHENE-IMIDAZOPYRIDINES | 4SC AG (DE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278833-A1 | THIOPHENE-IMIDAZOPYRIDINES | PIKFYVE, PIP4K2B, PIP5K1B | PLK1 642/4885PLK3 1528/4885CDK2 479/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | PLK1 353/4885PLK3 305/4885CDK2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.